Patients who had suffered chronic GVHD after an allogeneic PBSCT were evaluated using a new chronic GVHD grading system. The study included 36 consecutive adult patients with hematological diseases, who survived at least until day 90 following allogeneic PBSCT and who could be evaluated for chronic GVHD. Extensive skin involvement was observed in five patients, thrombocytopenia in 14, and progressive-type onset in 10, while grade 1 chronic GVHD appeared in 21 patients, grade 2 in 10, and grade 3 in five. There was a significant difference in the probability of relapse between the groups with grade 1 and 2 þ 3 chronic GVHD (55.3 vs 16.4%, P ¼ 0.0211). The difference was particularly marked in patients with highrisk hematological malignancies (grade 1 vs grade 2 þ 3, 75 vs 0%, P ¼ 0.0115). With a median follow-up of 12 months (range, 4-52 months), 22 (66.1%) patients were still alive. The estimated 2-year survival rate for the whole population was 57.6%, while that for the group with chronic GVHD grade 1 and grade 2 þ 3 was 53.5 and 56.3%, respectively (P ¼ 0.4387). Accordingly, there was a significant difference in the probability of relapse between the groups with grade 1 and grade 2 þ 3 chronic GVHD.
The classical Seattle system 1 for grading chronic GVHD (limited vs extensive) has limitations in practice, because it does not stratify patients according to outcome and includes an extremely heterogenous population among those needing treatment. According to the study by Akpek et al 2 , extensive skin involvement (ESI), thrombocytopenia (o100 Â 10 9 /l), and progressive-type onset (PTO) were all identified as significant predictors of poor prognosis in patients with chronic GVHD. Moreover, their clinical grading system has the potential to improve clinical management by adjusting therapy, improving the grouping of patients for clinical trials, and ensuring better communication between Centers. However, data are limited regarding the role of chronic GVHD, when using the new chronic GVHD grading system, in outcome of patients with hematological malignancies receiving allogeneic PBSCT. Although chronic GVHD is regarded as one of the main causes of transplant-related mortality, a stronger graftversus-leukemia (GVL) effect may reduce relapse and improve survival in hematological malignancies. 3 Therefore, the current study evaluated patients who suffered chronic GVHD after allogeneic PBSCT using the new chronic GVHD grading system of Akpek et al 2 in order to establish the impact of chronic GVHD on relapse and survival following allogeneic PBSCT in hematological malignancies.
Materials and methods

Transplantation procedure
The current study evaluated 36 consecutive adult patients with hematological diseases, who survived at least until day 90 following allogeneic PBSCT and who could be evaluated for chronic GVHD. Peripheral blood stem cells were collected from HLA-matched sibling donors mobilized with G-CSF and/or GM-CSF. Hematological diseases enrolled included AML (n ¼ 27), CML (n ¼ 4), MDS (n ¼ 2), NHL (n ¼ 2), and multiple myeloma (n ¼ 1), with 22 of standard-risk and 14 of high-risk disease status. Patient characteristics are summarized in Table 1 . Median patient age was 36 years (range, 17-54 years). Male-tofemale ratio was 20:16. Conditioning regimens were adopted according to underlying hematological diseases or patient status. All patients received unmanipulated PBSCs at day 0 from their donors. PBSCs were mobilized with 10 mg/kg/day G-CSF (Filgrastim, Leukokine with 5 mg/kg/day G-CSF and 5 mg/kg/day GM-CSF for 5 days, or with a sequential regimen (n ¼ 12) with 10 mg/kg/ day GM-CSF alone for 3 days followed by 10 mg/kg/day G-CSF alone for 2-3 days from HLA-matched sibling donors, as previously reported. 4, 5 Leukaphereses were performed using a Fenwal CS 3000 þ s blood cell separator (Baxter, Healthcare, Deerfield, IL, USA) with acid-citratedextrose as the anticoagulant. For successful transplantation, the minimum target number of MNCs and CD34 þ cells was 43 Â 10 8 /kg and 43 Â 10 6 /kg, respectively. GvHD prophylaxis consisted of methotrexate (MTX) and cyclosporin A (CyA; Cipol-N s , Chong Kun Dang Pharm., Seoul, Korea). All patients were scheduled to receive MTX 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6, and 11. CyA was administered intravenously at a dose of 2.5-5 mg/kg/ day starting on the day before the PBSCT. Oral CyA, 6 mg/ kg/day, was substituted for intravenous therapy when tolerated. Starting on day 60, the oral CyA administration was reduced by 5% weekly, then maintained at a dose of 1.5 mg/kg/day until day 270 for patients without symptomatic chronic GVHD. A flat CyA dose of 75 mg/day was continuously administered to prevent flare-up of chronic GVHD in patients with a history of symptomatic extensive chronic GVHD, until at least 2 years after day 270. After 2 years, if the patient did not manifest chronic GVHD symptoms or laboratory abnormalities, CyA was discontinued within 3 months. The doses of CyA were adjusted if necessary and the last dose of MTX was omitted for patients with severe mucositis or impaired renal function. Acute and chronic GVHD were graded and staged according to a consensus conference on acute GVHD grading 6 and clinicopathological classification of GVHD, 7 respectively. First-line treatment for chronic GVHD was stratified according to risk group: a combination of CyA and steroids for the high-risk group (platelet count X100 Â 10 9 /l) or just steroids for the low-risk group (platelet count o100 Â 10 9 /l). MMF was added at a dose of 1.5 or 2 g daily and the steroids were tapered in the refractory cases. A tapering schedule for steroids was a dose reduction of 0.2 mg/kg/week. The dose of MMF was escalated to 2 g/day if patients who received a dose of 1.5 g/ day had progressive GVHD. For patients with chronic GVHD, appropriate supportive care, including sun-block cream, skin lotion, or artificial tears, was provided, and prophylaxes for various infectious diseases were also administered. Doses of MMF were slowly tapered over at least 9 months in responsive patients. Additional systemic treatments, including antithymocye globulin (ATG), tacrolimus, and thalidomide or PUVA therapy, were provided for patients who were refractory to previous treatments. All patients were nursed in isolation with laminar airflow systems and received prophylactic antibiotics for various infections. All blood-derived transfusion products were irradiated prior to use.
Chronic GVHD grading
A comparison of clinical outcomes was made using the new chronic GVHD grading system of Akpek et al 2, 8 as follows: a prognostic score (PS) for each patient was calculated based on three risk factors, including the ESI, platelet count, and progressive onset of chronic GVHD. The PS was then calculated according to the following formula: PS ¼ (1.949 (skin extent)) þ (1.293 (platelets)) þ (0.514 (type of onset)). The following conditions were applied: (1) if the extent of skin involvement was more than 50% of the BSA, score 1, otherwise score 0; (2) if the platelet count was less than 100,000 cells/ml, score 1, otherwise score 0; and (3) if the chronic GVHD was of progressive onset, score 1, otherwise score 0. As such, chronic GVHD was graded according to the PS: Grade 1 (favorable risk): PS ¼ 1; Grade 2 (intermediate risk): PSo2, Grade 3 (high risk): PSX2.
Definitions
The day of stem cell infusion was defined as day 0. WBC engraftment was defined as the number of days taken to achieve ANC 40.5 Â 10 9 /l for 3 consecutive days. Platelet engraftment was defined as the time taken to achieve platelets 420 Â 10 9 /l without requiring transfusion. Skin biopsies were taken from all patients with skin rashes. Overall survival (OS) was based on time from the transplantation until death from any cause. Relapse-free survival was defined as the time from transplantation until relapse or death in complete remission (CR), by whatever cause. The probability of relapse was defined as the time from transplantation until relapse. Standard-risk diseases were defined as hematological malignancies, including acute leukemia or aggressive lymphoma of first CR or chronic-phase CML, while high-risk diseases (or diseases with a high risk of relapse) were defined as acute leukemia in more than first CR, Philadelphia þ acute lymphoblastic leukemia, advanced-phase chronic myelogenous leukemia (CML), primary refractory, or multiple relapsed malignancies.
Statistics
Clinical characteristics and transplant outcomes of patients were compared using nonparametric statistical methods including Fisher's exact test or Mann-Whitney's U-test. Survival analyses of OS, disease-free survival (DFS), and the cumulative incidence of relapse were conducted using the Kaplan-Meier method. A log rank test was also used for a survival analysis based on the grades of chronic GVHD. A cutoff P-value of 0.05 was adopted for all statistical analyses. Statistical data were obtained using an SPSS software package (SPSS 10.0 Inc., Chicago, IL, USA).
Results
Transplantation outcomes
Clinical outcomes are summarized in /kg for the high-risk group, respectively. There was no difference in the incidence of acute or chronic GVHD between the two groups.
Chronic GVHD grading ESI was observed in five patients, thrombocytopenia in 14, and PTO in 10. Grade 1 chronic GVHD appeared in 21 patients (58.3%), grade 2 in 10 (27.8%), and grade 3 in five (13.9%) ( Table 4 ). There was no difference in the incidence of each grade of chronic GVHD between the standard and high-risk groups.
Overall survival and probability of relapse There was no difference in OS between the grade 1 and grade 2 þ 3 groups (Figure 1a) . However, the difference in probability of relapse was significant between the groups with grade 1 and 2 þ 3 chronic GVHD (55.3 vs 16.4%, P ¼ 0.0211) (Figure 1a) . The difference was outstanding especially in patients with high-risk hematological malignancies (grade 1 vs grade 2 þ 3, 75.0 vs 0.0%, P ¼ 0.0115) (Figure 1b) . Relapse-free survival was better in the grade 2 þ 3 group than in the grade 1 group, with a marginal significance in patients with high-risk diseases. With a median follow-up of 12 months (range, 4-52 months), 22 patients (66.1%) were still alive. The estimated 2-year survival rate for the whole population was 57.6%, while that for the group with chronic GVHD grade 1 and grade 2 þ 3 was 53.5 and 56.3%, respectively (P ¼ 0.4387) (Figure 1a ).
Discussion
Prediction of outcome of patients with chronic GVHD may be important in determining the intensity of immunosuppressive therapy. In addition, a reliable predictive model could allow clinicians to design better clinical trials and facilitate improved communication between centers. Akpek et al 2, 8 developed a new prognostic scoring system based on three risk factors, including ESI, thrombocytopenia, and the onset type of chronic GVHD, that allows clinicians to identify diversity in outcome within 2 an ESI of more than 50% of the body surface area, hazard ratio (HR) of 7.0 (95% CI ¼ 3.6-13.4), thrombocytopenia (o100 Â 10 9 /l; HR, 3.6; 95% CI ¼ 1.9-6.8), and PTO (HR, 1.7; 95% CI ¼ 0.9-3.0) significantly influence disease-specific survival. Therefore, it would seem that the prognostic model based on three risk factors may be useful in grouping patients with similar outcomes. 2, 8 The result of classifying chronic GVHD using Akpek et al's new grading system seemed to be generally similar to that using the classical Seattle system in terms of defining the severity of chronic GVHD. In the current study, four out of 17 patients who were included in the group with extensive GVHD were classified as grade 1 according to the new system, while 17 in 19 limited chronic GVHD were classified as grade 1. The statistical analysis on 17 patients with extensive chronic GVHD showed that there was a significant difference in the incidence of probability of relapse among grade 1-3 (grade 1, n ¼ 4; grade 2, n ¼ 8; grade 3, n ¼ 5) chronic GVHD according to Akpek et al's new grading system (P ¼ 0.0037).
Chronic GVHD is believed to harbor a beneficial GVL effect resulting in fewer leukemia relapses. 9, 10 Conversely, it may also be associated with more late deaths. Gratwohl et al 11 demonstrated that limited chronic GVHD reduced the incidence of relapse to the same extent as extensive chronic GVHD, yet had no impact on TRM, thereby producing the best survival with an HR of 0.48 (0.32-0.71). Previous investigators 3, 12 have also reported that patients who developed extensive chronic GVHD had a relatively short progression-free survival due to a relatively high GVHD-related mortality without the benefit of fewer relapses. In addition, Zaucha et al 13 reported that the presence of extensive chronic GVHD showed no suggestion of being associated with a decreased risk of relapse. Yet, even though severe chronic GVHD is regarded as one of the main causes of transplant-related mortality, a stronger GVL effect may still reduce relapse and improve survival, especially in advanced stage hematological malignancies. Grigg et al 14 demonstrated that extensive chronic GVHD resulted in a significantly lower relapse rate than did limited chronic GVHD in patients with advanced leukemia. The current authors also previously reported that extensive chronic GVHD played a positive role in preventing relapse in patients with a high risk of relapse. 15 The incidence of acute GVHD seemed to be high compared with that in previous reports. As a possible explanation for this, because patients who died before day 90 or without chronic GVHD were excluded from this study, a relatively high number of patients with acute GVHD were included in the current study. This suggested that the number of patients who suffered de novo chronic GVHD was small in our trial.
The current study of allogeneic PBSCT found a significantly lower probability of relapse in the group with grade 2 þ 3 chronic GVHD than in the group with grade 1 chronic GVHD, especially in patents with advanced hematological malignancies, yet there was no difference in OS between the two groups. The lower level of significance as regards the difference in relapse-free survival between the grade 1 and grade 2 þ 3 chronic GVHD groups in patients with high risk diseases could be explained by the fact that the better relapse-free survival rate caused by a stronger GVL effect in the grade 2 þ 3 chronic GVHD group was offset by a higher GVHD-related death rate. Thus, a meticulous therapeutic approach that takes account of the severity of chronic GVHD is needed to produce a survival advantage in specific clinical situations where standard allogeneic transplantation by itself does not lead to good survival, such as high-risk ALL (pre-B ALL or Philadelphia chromosome positive ALL), primary refractory leukemia, or CML in blast crisis, where an intentionally greater GVHD or GVL effect is needed. 16 In a previous study, 17 chronic GVHD was associated with a decreased risk of relapse and no significant increase in deaths in complete remission, thereby leading to an increased duration of both disease-free survival and OS through the induction of a strong GVL effect in patients with advanced leukemia. Moreover, in the current study, for patients with a high risk of relapse, the induction of chronic GVHD over moderate severity would appear to be acceptable to minimize risk of relapse, based on inducing a potent graft-versus-disease effect. However, we admit that our Table 4 Chronic GVHD classification and grading system results should be interpreted with caution because of the limitations of the current study including a relatively small number of patients. A larger study analyzing survival data with this new grading system for chronic GVHD is warranted.
In conclusion, a significant difference in relapse probability was found between groups with grade 1 and 2 þ 3 chronic GVHD. Therefore, the role of advanced chronic GVHD needs to be addressed, especially in patients with high-risk hematological malignancies.
